We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review

Published: April 2019
Pages: 53
Code: 03EBFC719FA36726EC2FD91C24CC4C23
Format: PDF
Publisher GlobalData
From Add to basket
$ 125.00
Provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Additonal Information

  • - Business description – A detailed description of the company’s operations and business divisions.
  • - Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • - Company history – Progression of key events associated with the company.
  • - Major products and services – A list of major products, services and brands of the company.
  • - Key competitors – A list of key competitors to the company.
  • - Key employees – A list of the key executives of the company.
  • - Executive biographies – A brief summary of the executives’ employment history.
  • - Key operational heads – A list of personnel heading key departments/functions.
  • - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • - Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
  • Highlights
  • Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Its products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.
  • Genmab AS Key Recent Developments
  • Mar 29,2019 Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
  • Mar 11,2019 Genmab names Marisol Peron as head of communications and investor relations
  • Feb 25,2019 Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
  • Feb 20,2019 Genmab 2018 annual report

Companies Mentioned

Teva Pharmaceutical Industries Ltd
NeuroSearch AS
Medical Prognosis Institute A/S
Genentech Inc
Dansk Biotek
Biogen Inc
Bavarian Nordic A/S

Reasons to buy

You get detailed information about the company and its operations to identify potential customers and suppliers. The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted. Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Gain key insights into the company for academic or business research. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Note: Some sections may be missing if data is unavailable for the company
Add to basket
  • Table of Contents
  • Table of Contents
  • List of Tables
  • List of Figures
  • Section 1 - About the Company
  • Genmab A/S - Key Facts
  • Genmab A/S - Key Employees
  • Genmab A/S - Key Employee Biographies
  • Genmab A/S - Major Products and Services
  • Genmab A/S - History
  • Genmab A/S - Company Statement
  • Genmab A/S - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Section 2 – Company Analysis
  • Company Overview
  • Genmab A/S - Business Description
  • R&D Overview
  • Genmab A/S - Corporate Strategy
  • Genmab A/S - SWOT Analysis
  • SWOT Analysis - Overview
  • Genmab A/S - Strengths
  • Genmab A/S - Weaknesses
  • Genmab A/S - Opportunities
  • Genmab A/S - Threats
  • Genmab A/S - Key Competitors
  • Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
  • Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Genmab A/S, Recent Deals Summary
  • Section 5 – Company’s Recent Developments
  • Mar 29, 2019: Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
  • Mar 11, 2019: Genmab names Marisol Peron as head of communications and investor relations
  • Feb 25, 2019: Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
  • Feb 20, 2019: Genmab 2018 annual report
  • Nov 26, 2018: Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
  • Nov 14, 2018: Genmab reports financial results for the first nine months of 2018
  • Nov 01, 2018: Genmab Announces Data to be Presented at 2018 ASH Annual Meeting
  • Oct 29, 2018: Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
  • Oct 21, 2018: Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
  • Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About GlobalData
  • Contact Us
  • Disclaimer
  • List of Tables
  • Genmab A/S, Key Facts
  • Genmab A/S, Key Employees
  • Genmab A/S, Key Employee Biographies
  • Genmab A/S, Major Products and Services
  • Genmab A/S, History
  • Genmab A/S, Subsidiaries
  • Genmab A/S, Key Competitors
  • Genmab A/S, Ratios based on current share price
  • Genmab A/S, Annual Ratios
  • Genmab A/S, Annual Ratios (Cont...1)
  • Genmab A/S, Interim Ratios
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Genmab A/S, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
  • List of Figures
  • Genmab A/S, Performance Chart (2014 - 2018)
  • Genmab A/S, Ratio Charts
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Keywords
;